Bae Min Sun, Sung Janice S, Bernard-Davila Blanca, Sutton Elizabeth J, Comstock Christopher E, Morris Elizabeth A
Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY.
J Breast Imaging. 2020 Feb;2(1):29-35. doi: 10.1093/jbi/wbz083. Epub 2020 Jan 15.
To determine survival outcomes in women with breast cancer detected at combined screening with breast MRI and mammography versus screening mammography alone.
This is an institutional review board-approved retrospective study, and the need for informed consent was waived. A total of 3002 women with an increased risk of breast cancer were screened between 2001 and 2004. Of the 3002 women, 1534 (51.1%) had 2780 combined screenings (MRI and mammography) and 1468 (48.9%) had 4811 mammography-only screenings. The test and the Kaplan-Meier method were used to compare cancer detection rates and survival rates.
The overall cancer detection rate was significantly higher in the MRI plus mammography group compared with the mammography-only group (1.4% [40 of 2780] vs 0.5% [23 of 4811]; < 0.001). No interval cancers occurred in the MRI plus mammography group, whereas 9 interval cancers were found in the mammography-only group. During a median follow-up of 10.9 years (range: 0.7 to 15.2), a total of 11 recurrences and 5 deaths occurred. Of the 11 recurrences, 6 were in the MRI plus mammography group and 5 were in the mammography-only group. All five deaths occurred in the mammography-only group. Disease-free survival showed no statistically significant difference between the two groups ( 0.32). However, overall survival was significantly improved in the MRI plus mammography group ( = 0.002).
Combined screening with MRI and mammography in women at elevated risk of breast cancer improves cancer detection and overall survival.
确定在联合使用乳腺磁共振成像(MRI)和乳腺钼靶检查进行筛查与仅使用乳腺钼靶检查进行筛查时,乳腺癌女性患者的生存结局。
这是一项经机构审查委员会批准的回顾性研究,无需知情同意。2001年至2004年期间,共对3002名乳腺癌风险增加的女性进行了筛查。在这3002名女性中,1534名(51.1%)接受了2780次联合筛查(MRI和乳腺钼靶检查),1468名(48.9%)接受了4811次仅乳腺钼靶检查。采用检验和Kaplan-Meier方法比较癌症检出率和生存率。
与仅乳腺钼靶检查组相比,MRI加乳腺钼靶检查组的总体癌症检出率显著更高(1.4%[2780例中的40例]对0.5%[4811例中的23例];<0.001)。MRI加乳腺钼靶检查组未发生间期癌,而仅乳腺钼靶检查组发现9例间期癌。在中位随访10.9年(范围:0.7至15.2年)期间,共发生11例复发和5例死亡。在11例复发中,6例在MRI加乳腺钼靶检查组,5例在仅乳腺钼靶检查组。所有5例死亡均发生在仅乳腺钼靶检查组。两组间无病生存率无统计学显著差异(0.32)。然而,MRI加乳腺钼靶检查组的总生存率显著提高(=0.002)。
对乳腺癌风险升高的女性联合使用MRI和乳腺钼靶检查进行筛查可提高癌症检出率和总生存率。